Literature DB >> 22973037

Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion.

Moanaro Biswas1, John B Johnson, Sandeep R P Kumar, Griffith D Parks, Subbiah Elankumarana, Elankumaran Subbiah.   

Abstract

Newcastle disease virus (NDV), an avian paramyxovirus, is inherently tumor selective and is currently being considered as a clinical oncolytic virus and vaccine vector. In this study, we analyzed the effect of complement on the neutralization of NDV purified from embryonated chicken eggs, a common source for virus production. Fresh normal human serum (NHS) neutralized NDV by multiple pathways of complement activation, independent of neutralizing antibodies. Neutralization was associated with C3 deposition and the activation of C2, C3, C4, and C5 components. Interestingly, NDV grown in mammalian cell lines was resistant to complement neutralization by NHS. To confirm whether the incorporation of regulators of complement activity (RCA) into the viral envelope afforded complement resistance, we grew NDV in CHO cells stably transfected with CD46 or HeLa cells, which strongly express CD46 and CD55. NDV grown in RCA-expressing cells was resistant to complement by incorporating CD46 and CD55 on virions. Mammalian CD46 and CD55 molecules on virions exhibited homologous restriction, since chicken sera devoid of neutralizing antibodies to NDV were able to effectively neutralize these virions. The incorporation of chicken RCA into NDV produced in embryonated eggs similarly provided species specificity toward chicken sera.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22973037      PMCID: PMC3497656          DOI: 10.1128/JVI.00886-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

Review 1.  The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider.

Authors:  Richard Vile; Dale Ando; David Kirn
Journal:  Cancer Gene Ther       Date:  2002-12       Impact factor: 5.987

2.  Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.

Authors:  K Ikeda; H Wakimoto; T Ichikawa; S Jhung; F H Hochberg; D N Louis; E A Chiocca
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Recombinant Newcastle disease virus as a vaccine vector.

Authors:  T Nakaya; J Cros; M S Park; Y Nakaya; H Zheng; A Sagrera; E Villar; A García-Sastre; P Palese
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  The complement response against an oncolytic virus is species-specific in its activation pathways.

Authors:  Hiroaki Wakimoto; Keiro Ikeda; Tatsuya Abe; Tomotsugu Ichikawa; Fred H Hochberg; R Alan B Ezekowitz; Mark S Pasternack; E Antonio Chiocca
Journal:  Mol Ther       Date:  2002-03       Impact factor: 11.454

5.  A novel chicken membrane-associated complement regulatory protein: molecular cloning and functional characterization.

Authors:  N Inoue; A Fukui; M Nomura; M Matsumoto; Y Nishizawa; K Toyoshima; T Seya
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

6.  Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1.

Authors:  H M Friedman; L Wang; M K Pangburn; J D Lambris; J Lubinski
Journal:  J Immunol       Date:  2000-10-15       Impact factor: 5.422

7.  Reduced sensitivity to human serum inactivation of enveloped viruses produced by pig cells transgenic for human CD55 or deficient for the galactosyl-alpha(1-3) galactosyl epitope.

Authors:  Saema Magre; Yasuhiro Takeuchi; Gillian Langford; Andrew Richards; Clive Patience; Robin Weiss
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells.

Authors:  Maria L Barilla-LaBarca; M Kathryn Liszewski; John D Lambris; Dennis Hourcade; John P Atkinson
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

Review 9.  Safety and clinical usage of newcastle disease virus in cancer therapy.

Authors:  Han Yuen Lam; Swee Keong Yeap; Mehdi R Pirozyan; Abdul Rahman Omar; Khatijah Yusoff; Abd Aziz Suraini; Noorjahan Banu Alitheen
Journal:  J Biomed Biotechnol       Date:  2011-10-26

Review 10.  The relevance of complement to virus biology.

Authors:  Clare E Blue; O Brad Spiller; David J Blackbourn
Journal:  Virology       Date:  2004-02-20       Impact factor: 3.616

View more
  23 in total

1.  Hepatitis B virus inhibits the expression of complement C3 and C4, in vitro and in vivo.

Authors:  Chengliang Zhu; Hui Song; Fengxia Xu; Wei Yi; Fang Liu; Xinghui Liu
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

2.  Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy.

Authors:  P R A Buijs; G van Amerongen; S van Nieuwkoop; T M Bestebroer; P R W A van Run; T Kuiken; R A M Fouchier; C H J van Eijck; B G van den Hoogen
Journal:  Cancer Gene Ther       Date:  2014-09-26       Impact factor: 5.987

Review 3.  Oncolytic viruses and their application to cancer immunotherapy.

Authors:  E Antonio Chiocca; Samuel D Rabkin
Journal:  Cancer Immunol Res       Date:  2014-04       Impact factor: 11.151

Review 4.  Interactions of viruses and the humoral innate immune response.

Authors:  Bailey E Maloney; Krishani Dinali Perera; Danielle R D Saunders; Naemi Shadipeni; Sherry D Fleming
Journal:  Clin Immunol       Date:  2020-02-04       Impact factor: 3.969

Review 5.  Paramyxovirus activation and inhibition of innate immune responses.

Authors:  Griffith D Parks; Martha A Alexander-Miller
Journal:  J Mol Biol       Date:  2013-09-20       Impact factor: 5.469

6.  CD59 association with infectious bronchitis virus particles protects against antibody-dependent complement-mediated lysis.

Authors:  Yanquan Wei; Yanhong Ji; Huichen Guo; Xiaoying Zhi; Shichong Han; Yun Zhang; Yuan Gao; Yanyan Chang; Dan Yan; Kangyu Li; Ding Xiang Liu; Shiqi Sun
Journal:  J Gen Virol       Date:  2017-10-25       Impact factor: 3.891

7.  A novel factor I activity in Nipah virus inhibits human complement pathways through cleavage of C3b.

Authors:  John B Johnson; Viktoriya Borisevich; Barry Rockx; Griffith D Parks
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

8.  Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy.

Authors:  Raghunath Shobana; Siba K Samal; Subbiah Elankumaran
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

9.  Parainfluenza virus 5 upregulates CD55 expression to produce virions with enhanced resistance to complement-mediated neutralization.

Authors:  Yujia Li; John B Johnson; Griffith D Parks
Journal:  Virology       Date:  2016-08-06       Impact factor: 3.616

10.  Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.

Authors:  Xing Cheng; Weijia Wang; Qi Xu; James Harper; Danielle Carroll; Mark S Galinski; JoAnn Suzich; Hong Jin
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.